News | August 22, 2017

CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies Collaboration expands CRISPR Therapeutics’ efforts in immuno-oncology ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE...

News | August 15, 2017

Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares OXFORD, United Kingdom and MARLBOROUGH, Mass., August 15, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company...

News | August 15, 2017

Binary Fountain and Kyruus Announce Partnership to Enhance Patient Acquisition and Engagement for Health Systems by Kyruus, on Aug 15, 2017 8:55:42 AM The seamless integration of Binary Star Ratings and Kyruus ProviderMatch for Consumers will enable health systems to...

News | August 1, 2017

Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions Evanston, Ill., August 1, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today...

News | September 27, 2017

Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...

News | September 18, 2017

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial Oxfordshire, UK, 18th September 2017 – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative...